Cover image for Vol. 121 Issue 1

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.901

ISI Journal Citation Reports © Ranking: 2013: 38/203 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

  1. Original Articles

    1. Disease Site

      Soft Tissue and Bone Sarcoma
      Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma—Associations with tumor phenotype and survival

      Jason U. Tilan, Mark Krailo, Donald A. Barkauskas, Susana Galli, Haifa Mtaweh, Jessica Long, Hongkun Wang, Kirsten Hawkins, Congyi Lu, Dima Jeha, Ewa Izycka-Swieszewska, Elizabeth R. Lawlor, Jeffrey A. Toretsky and Joanna B. Kitlinska

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29090

      Elevated systemic levels of neuropeptide Y, an EWS-FLI1 transcriptional target that is highly expressed in Ewing sarcoma, are associated with unfavorable clinical features, such as pelvic localization, the presence of metastases, and bone origin. Conversely, high activity of dipeptidyl peptidase IV in patients' sera is associated with a better prognosis, suggesting a potential role for the protease in antitumor immune response.

    2. Discipline

      Complementary Medicine
      Cancer survivors' disclosure of complementary health approaches to physicians: The role of patient-centered communication

      Stephanie J. Sohl, Laurel A. Borowski, Erin E. Kent, Ashley Wilder Smith, Ingrid Oakley-Girvan, Russell L. Rothman and Neeraj K. Arora

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29138

      Analyses of a population-based sample of cancer survivors support the idea that improving the overall patient centeredness of cancer follow-up care and improving the disclosure of complementary health approaches to physicians are potentially synergistic clinical goals.

    3. Disease Site

      Hematologic Malignancies
      Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

      Avichai Shimoni, Yulia Volchek, Maya Koren-Michowitz, Nira Varda-Bloom, Raz Somech, Noga Shem-Tov, Ronit Yerushalmi and Arnon Nagler

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29141

      Nilotinib is relatively safe and effective as prophylactic therapy for the prevention of relapse after allogeneic stem cell transplantation in the setting of advanced chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia.

  2. Erratum

    1. You have free access to this content
  3. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

      Meagan S. Barbee, Ajay Nooka, Jonathan L. Kaufman, Sungjin Kim, Zhengjia Chen, Leonard T. Heffner Jr, Sagar Lonial and R. Donald Harvey

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29136

      The findings of this study validate the use of the International Myeloma Working Group criteria in a phase 1 setting but bring into question the boundaries of response set forth by the criteria in a phase 1 population. It is suggested that normalization of the free light chain ratio be considered in future phase 1 studies as an early indicator of response to promote rapidity in moving novel therapies and combinations into the phase 2 evaluation.

    2. Discipline

      Clinical Trials
      Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

      Robert C. Doebele, David Spigel, Mustapha Tehfe, Sachdev Thomas, Martin Reck, Sunil Verma, Janice Eakle, Frederique Bustin, Jerome Goldschmidt Jr, Dachuang Cao, Ekaterine Alexandris, Sergey Yurasov, D. Ross Camidge and Philip Bonomi

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29132

      Although a statistically significant improvement in progression-free survival is not achieved in this phase 2 randomized study, ramucirumab shows evidence of clinical activity in combination with pemetrexed-platinum chemotherapy in patients with nonsquamous non–small cell lung cancer. The addition of ramucirumab does not result in new or unexpected safety findings.

    3. Disparities Research
      A mixed-methods examination of communication between oncologists and primary care providers among primary care physicians in underserved communities

      Megan Johnson Shen, Maria Binz-Scharf, Tom D'Agostino, Natasha Blakeney, Elisa Weiss, Margo Michaels, Shilpa Patel, M. Diane McKee and Carma L. Bylund

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29131

      Primary care physicians (PCPs) treating underserved, minority patients want to be more involved in patient care during and after cancer treatment, but significant communication gaps occur between oncologists and PCPs during this time. A focus on improving PCP-oncologist communication during treatment could reduce the burden on oncologists and improve patient satisfaction and care, specifically among underserved, minority populations.

    4. Epidemiology
      The rise in metastasectomy across cancer types over the past decade

      Edmund K. Bartlett, Kristina D. Simmons, Heather Wachtel, Robert E. Roses, Douglas L. Fraker, Rachel R. Kelz and Giorgos C. Karakousis

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29134

      From 2000 through 2011, metastasectomy was increasingly performed for patients with colorectal cancer, lung cancer, breast cancer, and melanoma. Inpatient mortality decreased despite increasing patient comorbidity. The increased performance of metastasectomy was predominately driven by high-volume institutions.

    5. Disease Site

      Soft Tissue and Bone Sarcoma
      Significant association between human osteosarcoma and simian virus 40

      Elisa Mazzoni, Maria Serena Benassi, Alfredo Corallini, Giovanni Barbanti-Brodano, Angelo Taronna, Piero Picci, Giovanni Guerra, Antonio D'Agostino, Lorenzo Trevisiol, Pier Francesco Nocini, Maria Vittoria Casali, Giuseppe Barbanti-Brodano, Fernanda Martini and Mauro Tognon

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29137

      Patients with osteosarcoma carry at high prevalence of simian virus 40 antibodies. The results of the current study indicate that these patients could be treated with antivirals.

    6. Discipline

      Psychosocial Oncology
      Experiencing reproductive concerns as a female cancer survivor is associated with depression

      Jessica R. Gorman, H. Irene Su, Samantha C. Roberts, Sally A. Dominick and Vanessa L. Malcarne

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29133

      Addressing the reproductive concerns experienced by young adult female cancer survivors is an important element of comprehensive survivorship care and has the potential to improve psychosocial health.

    7. Epidemiology
      Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration: A study of the Veterans Affairs health care system

      Jose P. Zevallos, Christine M. Hartman, Jennifer R. Kramer, Erich M. Sturgis and Elizabeth Y. Chiao

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29122

      Although the incidence of thyroid cancer has doubled within the Veterans Affairs health care system, a nearly 5-fold increase in the use of thyroid ultrasound and a nearly 7-fold increase in the use of fine-needle aspiration occurred between 2000 and 2012. These findings suggest that the increase in thyroid cancer incidence may be related to increases in the use of ultrasound and fine-needle aspiration.

    8. Outcomes Research
      Predictors of health care utilization in adult survivors of childhood cancer exposed to central nervous system–directed therapy

      Cara I. Kimberg, James L. Klosky, Nan Zhang, Tara M. Brinkman, Kirsten K. Ness, Deo Kumar Srivastava, Leslie L. Robison, Melissa M. Hudson and Kevin R. Krull

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29121

      Survivors of childhood cancer treated with central nervous system–directed therapy are at risk for poor health care utilization in part because of reduced global cognition. Educational approaches regarding recommended health care should be modified to ensure comprehension by survivors with neurocognitive impairment.

    9. Disease Site

      Gastrointestinal Disease
      Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?

      Timothy J. Price, Carol Beeke, Shahid Ullah, Robert Padbury, Guy Maddern, David Roder, Amanda R. Townsend, James Moore, Amitesh Roy, Yoko Tomita and Christos Karapetis

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29129

      The primary site of metastatic colorectal cancer impacts survival outcomes. Stratification by left and right colon should be considered in trial design.

    10. Discipline

      Outcomes Research
      Critical evaluation of the scientific content in clinical practice guidelines

      Zaid M. Abdelsattar, Bradley N. Reames, Scott E. Regenbogen, Samantha Hendren and Sandra L. Wong

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29124

      There is significant variation in the development processes and scientific content of clinical practice guidelines. Differences in interpreting the evidence and conflicting recommendations call for improving the quality and consistency of guidelines.

    11. Quality of Life
      Impact of colorectal cancer diagnosis and treatment on health-related quality of life among older Americans: A population-based, case-control study

      Caroleen Quach, Hanna K. Sanoff, Grant R. Williams, Jessica C. Lyons and Bryce B. Reeve

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29125

      Older Americans with colorectal cancer, particularly later-stage patients, experience significant decrements in physical and mental health aspects of health-related quality of life, including activities of daily living impairment and being at greater risk for major depressive disorder, following diagnosis and treatment compared to matched noncancer controls.

    12. Psychosocial Oncology
      Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer care

      Lynne I. Wagner, Julian Schink, Michael Bass, Shalini Patel, Maria Varela Diaz, Nan Rothrock, Timothy Pearman, Richard Gershon, Frank J. Penedo, Steven Rosen and David Cella

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29104

      The successful implementation of an electronic patient-reported outcome (ePRO) system using the Patient Reported Outcomes Measurement Information System is demonstrated for the precise, valid, and robust measurement of common cancer-related symptoms with electronic health record integration for immediate clinician notification and with triage for identified problems. Six hundred thirty-six gynecologic oncology outpatients complete the ePRO assessment, and they demonstrate its feasibility and provide information on the most common symptom-related and psychosocial concerns.

  4. Editorials

    1. Inherited predisposition to endometrial cancer: Moving beyond Lynch syndrome

      Zsofia K. Stadler and Mark E. Robson

      Article first published online: 5 NOV 2014 | DOI: 10.1002/cncr.29107

      A number of predisposition syndromes include endometrial cancer as a component tumor. These can generally be identified on the basis of the family history and the individual phenotype.

  5. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with cowden and cowden-like syndromes: An international, multicenter, prospective study

      Haider Mahdi, Jessica L. Mester, Emily A. Nizialek, Joanne Ngeow, Chad Michener and Charis Eng

      Article first published online: 5 NOV 2014 | DOI: 10.1002/cncr.29106

      In this prospective study of endometrial cancer patients with the Cowden phenotype, clinical predictors of a germline phosphatase and tensin homolog (PTEN) mutation include a younger age, macrocephaly, a high Cleveland Clinic score, a low PTEN protein level, and coexisting renal cancer. Endometrial cancer patients with germline KLLN promoter methylation are likely to have an increased phenotypic load and to present at younger ages similarly to those with a germline PTEN mutation. Thus, high-risk cancer surveillance and prophylactic surgery of the uterus may be considered for these patients similarly to those with PTEN mutations.

    2. Discipline

      Outcomes Research
      Health-related quality of life in older adult survivors of selected cancers: Data from the SEER-MHOS linkage

      Erin E. Kent, Anita Ambs, Sandra A. Mitchell, Steven B. Clauser, Ashley Wilder Smith and Ron D. Hays

      Article first published online: 4 NOV 2014 | DOI: 10.1002/cncr.29119

      The health-related quality of life of older adult survivors of less common cancers is compared to the health-related quality of life of older individuals with no cancer history on the basis of data from the Surveillance, Epidemiology, and End Results/Medicare Health Outcomes Survey linked data resource. Inferior health-related quality of life (particularly impaired physical health) is found among survivors of several cancer types; the greatest deficits are reported by those with multiple myeloma and pancreatic cancer.

    3. The symptom burden of treatment-naive patients with head and neck cancer

      Ehab Y. Hanna, Tito R. Mendoza, David I. Rosenthal, G. Brandon Gunn, Pamela Sehra, Emre Yucel and Charles S. Cleeland

      Article first published online: 4 NOV 2014 | DOI: 10.1002/cncr.29097

      Moderate to severe symptoms were found to be highly prevalent in the current study of treatment-naive patients with head and neck cancer, thereby demonstrating the importance of pretreatment symptom assessment and the need for symptom management together with disease treatment. Knowledge of disease-related (treatment-naive) symptom status is critical for evaluating the symptomatic benefit/burden of therapies for head and neck cancer.